In the Margins
Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes.
Most Read
Congress created business development companies in 1980 to support job growth and help emerging companies raise funds. As of 2023, there were 139 BDCs with $312 ...
The Vanguard board expects to add two new independent directors in early 2025 to fill seats that will be vacated when two long-serving independents retire. The ...
The bottom line: In the near term, it’s not likely that the roles and activities of mutual fund directors will change much. There will be no ...
The Securities and Exchange Commission this week said it found "deficiencies" and "weaknesses" in mutual funds' governance practices during examinations over the past four years. The ...